ChromaDex (NASDAQ:CDXC) Upgraded at StockNews.com

StockNews.com upgraded shares of ChromaDex (NASDAQ:CDXC) from a buy rating to a strong-buy rating in a research note published on Monday.

Several other research firms also recently weighed in on CDXC. HC Wainwright boosted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Roth Mkm boosted their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, November 6th.

ChromaDex Trading Up 4.0 %

CDXC stock opened at $5.66 on Monday. The firm has a 50 day simple moving average of $5.61 and a 200-day simple moving average of $5.02. The company has a market capitalization of $432.33 million, a P/E ratio of 566.57 and a beta of 2.21. ChromaDex has a twelve month low of $1.57 and a twelve month high of $7.97.

Insiders Place Their Bets

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the transaction, the director now directly owns 244,179 shares in the company, valued at approximately $1,511,468.01. This trade represents a 13.21 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 9.64% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ChromaDex

Several institutional investors and hedge funds have recently bought and sold shares of CDXC. D. E. Shaw & Co. Inc. grew its position in shares of ChromaDex by 1,785.9% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company’s stock worth $5,365,000 after acquiring an additional 957,665 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in ChromaDex by 288.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company’s stock worth $3,517,000 after acquiring an additional 492,148 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in ChromaDex by 189.0% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 506,186 shares of the company’s stock valued at $2,685,000 after purchasing an additional 331,014 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of ChromaDex during the 4th quarter valued at $1,647,000. Finally, Renaissance Technologies LLC boosted its position in shares of ChromaDex by 68.0% in the 4th quarter. Renaissance Technologies LLC now owns 712,788 shares of the company’s stock valued at $3,781,000 after purchasing an additional 288,588 shares during the period. Institutional investors and hedge funds own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.